BNP Paribas Financial Markets Has $263,000 Holdings in Emergent BioSolutions Inc. (NYSE:EBS)

BNP Paribas Financial Markets reduced its stake in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 65.0% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 31,470 shares of the biopharmaceutical company’s stock after selling 58,544 shares during the period. BNP Paribas Financial Markets owned about 0.06% of Emergent BioSolutions worth $263,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. American Century Companies Inc. grew its holdings in shares of Emergent BioSolutions by 240.9% in the second quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock valued at $6,015,000 after acquiring an additional 623,201 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in Emergent BioSolutions by 74.5% in the third quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock worth $6,192,000 after purchasing an additional 316,700 shares during the last quarter. Federated Hermes Inc. grew its stake in Emergent BioSolutions by 1,314.0% in the 2nd quarter. Federated Hermes Inc. now owns 273,287 shares of the biopharmaceutical company’s stock valued at $1,864,000 after purchasing an additional 253,960 shares during the period. Marshall Wace LLP increased its position in shares of Emergent BioSolutions by 75.4% during the 2nd quarter. Marshall Wace LLP now owns 542,813 shares of the biopharmaceutical company’s stock valued at $3,702,000 after purchasing an additional 233,341 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new stake in shares of Emergent BioSolutions during the 2nd quarter worth $1,576,000. Institutional investors own 78.40% of the company’s stock.

Analyst Ratings Changes

EBS has been the topic of several research reports. Benchmark boosted their target price on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. StockNews.com raised shares of Emergent BioSolutions from a “hold” rating to a “buy” rating in a research report on Thursday, December 12th. Finally, Rodman & Renshaw reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Emergent BioSolutions in a report on Friday, September 13th.

Emergent BioSolutions Stock Up 4.6 %

Shares of Emergent BioSolutions stock opened at $8.87 on Tuesday. The company’s fifty day simple moving average is $9.35 and its two-hundred day simple moving average is $8.73. Emergent BioSolutions Inc. has a 12-month low of $1.42 and a 12-month high of $15.10. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. The company has a market cap of $480.61 million, a P/E ratio of -2.16 and a beta of 1.59.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.